PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11454885-0	2001	Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.	Tamoxifen	106-115	epidermal growth factor receptor	Homo sapiens	9-41	
11454885-2	2001	HER2, epidermal growth factor receptor (EGFR), and p53 have all been suggested as possible markers of tamoxifen resistance.	Tamoxifen	102-111	epidermal growth factor receptor	Homo sapiens	6-38	
11454885-2	2001	HER2, epidermal growth factor receptor (EGFR), and p53 have all been suggested as possible markers of tamoxifen resistance.	Tamoxifen	102-111	epidermal growth factor receptor	Homo sapiens	40-44	
11454885-3	2001	The aim of this study was to investigate interactions between adjuvant treatment with tamoxifen and the content of EGFR, HER2, and p53 in steroid receptor-positive patients.	Tamoxifen	86-95	epidermal growth factor receptor	Homo sapiens	115-119	
11454885-9	2001	Patients with steroid receptor-positive tumors and positive immunohistochemical staining for HER2, EGFR or p53 benefited from treatment with tamoxifen for 1 year, although the latter variable contained independent prognostic information by itself.	Tamoxifen	141-150	epidermal growth factor receptor	Homo sapiens	99-103